Skip to Main Content

Prazosin for Alcohol Use Disorder

Conditions

Addictive Behaviors | Alcohol Addiction | Mental Health & Behavioral Research

Phase I-II

What is the purpose of this trial?

The purpose of this 12-week study is to see if a medication called Prazosin, which is an FDA approved medication for blood pressure, reduces alcohol intake and the desire to use alcohol in individuals with alcohol use disorder who have experienced some withdrawal symptoms now or in the past. We are trying to see if it will prevent or reduce alcohol intake and relapse, especially those related to stress and anxiety.

Participation involves weekly or biweekly visits to the Yale Stress Center in New Haven, as well as free weekly counseling sessions. Total estimated compensation is $830.

For information contact: Yale Stress Center at 1-877-Y-STUDIES (1-877-978-8343) or 203-737-5201, ana.makharashvili@yale.edu

  • Trial with
    National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  • Start Date
    03/29/2021
  • End Date
    01/15/2026

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/26/2021
  • Study HIC
    #2000029805